President Peggy Lu was invited to participate in Bridging the Gap 2019 (BTG2019)

The 10th Bridging the Gap (BTG) was held on March 15-17, 2019 at the Shangri-La Hotel, Fuzhou, China. Bridging the Gap (BTG) is one of the largest and most important conferences on the research and treatment of hematological malignancies in the Asia Pacific region, hosted by the Asia Pacific Hematology Consortium (APHCON), and more than 500 hematological malignancies attended the meeting. President Peggy was invited to participate in the meeting.

On the morning of March 16, after Huang Xiaojun, director of the Institute of Hematology, Peking University, and Professor Wang Jianxiang from the Hematology Hospital of the Chinese Academy of Medical Sciences, As the third Chinese speaker, President Peggy gave a report entitled "CAR-T Treatment for R/R B-ALL experience from Lu Daopei Hospital".

Up to now, Lu Daopei Hospital has completed more than 500 CAR-T clinical trial cases, and has become the single center with the largest number of CAR-T treatments in China and the world,  accumulated a lot of clinical experience.

It is showed that patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL)had a higher rate of remission by the study.

The Asia Pacific Hematology Consortium (APHCON) consists of hematologists and oncologists from 28 countries. The purpose is to advance the development of the blood oncology discipline through continuing education, cooperation and innovation.

BTG is an academic activity carried out under the APHCON organization. Most of the participants in the conference are hematology doctors in the Asia-Pacific region. The purpose is to introduce the latest blood disease diagnosis and treatment progress and strengthen international cooperation and exchanges. Improve the overall level of development in the field of hematology in the Asia Pacific region.

Lu Daopei Hospital will continue to strengthen sharing, exchange and cooperation with the international community, and fully promote the innovation of blood disease treatment technology to improve the overall level of blood disease treatment and the development of the whole industry.